Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

Aldose reductase (AR) inhibition has emerged as a strategic approach to mitigate the microvascular and macrovascular complications that characterise diabetes mellitus. Under hyperglycaemic conditions, ...

Researchers from ICTER have developed a fragment-based drug discovery method combined with microcrystal electron diffraction to design enzyme inhibitors at atomic resolution. The approach aims to ...

Aldose reductase (AR) has been a long-standing target for treating diabetic complications, but its structural similarity to related enzymes has made selective inhibition difficult. Off-target binding ...

In this second of three articles on The Sunday Times top 100 tech companies list, pharmaphorum is focusing on the first nine of 18 start-ups featuring in the hardware category. The list recognises the ...

Oxidative stress plays a pivotal role in the development of diabetes complications, both microvascular and cardiovascular. The metabolic abnormalities of diabetes cause mitochondrial superoxide ...

Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic ...

Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called ...

Background Hepatocellular carcinoma (HCC), one of the most prevalent cancers worldwide, has a high mortality owing to ...

Over the last several decades, the global incidence and prevalence of diabetes mellitus has increased significantly. The raised incidence rate is projected to continue as greater numbers of persons ...